Quoin Pharmaceuticals (NASDAQ: QNRX) will provide a corporate update and release first quarter 2026 financial results before the market opens on Thursday, May 7, 2026.
The company said the announcement will include an operational update highlighting key quarterly achievements, recent accomplishments, and financial highlights for the quarter ended March 31, 2026.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
None.
Negative
None.
News Market Reaction – QNRX
+9.27%
3 alerts
+9.27%News Effect
-4.4%Trough Tracked
+$998KValuation Impact
$11.76MMarket Cap
0.3xRel. Volume
On the day this news was published, QNRX gained 9.27%, reflecting a notable positive market reaction.
Argus tracked a trough of -4.4% from its starting point during tracking.
Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
This price movement added approximately $998K to the company's valuation, bringing the market cap to $11.76M at that time.
Net loss 2025:$15.8 millionNet loss 2024:$9.0 millionQ4 2025 net loss:$4.3 million+5 more
8 metrics
Net loss 2025$15.8 millionNet loss for year ended Dec 31, 2025
Net loss 2024$9.0 millionNet loss for year ended Dec 31, 2024
Q4 2025 net loss$4.3 millionNet loss for quarter ended Dec 31, 2025
Year-end cash$18.7 millionCash, cash equivalents and marketable securities at Dec 31, 2025
Private placement size$104.5 millionClosed private placement financing in Oct 2025, up to this amount
Warrant proceeds (placement)$88.0 millionPotential proceeds from warrant exercises in Oct 2025 placement
ADSs registered10,045,455 ADSsForm S-3 resale registration for selling shareholders
Warrant proceeds (shelf)$88.7 millionPotential cash to Quoin if accompanying warrants exercised
Market Reality Check
Price:$4.20Vol:Volume 24,483 vs 20-day a...
normal vol
$4.20Last Close
VolumeVolume 24,483 vs 20-day average 33,769 (relative volume 0.73).normal
TechnicalShares traded below the 200-day MA of 9.82, despite a 8.81% daily gain.
Peers on Argus
Scanner flagged 2 biotech peers (e.g., XBIO) moving down around -5%, while QNRX ...
2 Down
Scanner flagged 2 biotech peers (e.g., XBIO) moving down around -5%, while QNRX gained 8.81%. This divergence points to stock-specific interest around the earnings-date announcement.
Scheduled Q4 and full-year 2025 results with corporate update details.
Pattern Detected
The last earnings-date announcement saw a modest positive move of 5.36%, similar to today’s constructive reaction.
Recent Company History
Over recent months, Quoin has combined corporate and financial updates with significant regulatory and clinical milestones. A prior earnings-date notice on Mar 19, 2026 preceded Q4 and full-year 2025 results and a broader operational update, and the stock rose 5.36% over the next day. Today’s Q1 2026 earnings-date announcement follows that pattern of pairing scheduled results with corporate commentary.
Historical Comparison
+5.4% avg move · Prior earnings-date news led to an average move of 5.36%. Today’s 8.81% gain is larger but direction...
earnings date
+5.4%
Average Historical Moveearnings date
Prior earnings-date news led to an average move of 5.36%. Today’s 8.81% gain is larger but directionally consistent with that history.
Earnings-date releases have served as anchors for broader corporate and financial updates, with the prior event tied to Q4 and full-year 2025 results.
Regulatory & Risk Context
Active S-3 Shelf · $88.7 million
Shelf Active
Active S-3 Shelf Registration
2025-11-07
$88.7 millionregistered capacity
An effective Form S-3 registers the resale of up to 10,045,455 ADSs by selling shareholders. Quoin would not receive proceeds from these resales but could receive up to $88.7 million only if related warrants are exercised for cash, and the filing highlights substantial potential dilution relative to ADSs outstanding.
Market Pulse Summary
The stock moved +9.3% in the session following this news. A strong positive reaction aligns with how...
Analysis
The stock moved +9.3% in the session following this news. A strong positive reaction aligns with how prior earnings-date announcements influenced QNRX, where a similar notice on Mar 19, 2026 preceded a 5.36% gain. However, the stock still traded far below its 52-week high and under the 200-day MA, and an existing Form S-3 resale registration covering 10,045,455 ADSs underscores ongoing dilution and funding considerations.
Key Terms
form s-3, american depositary shares, warrants, fast track designation, +3 more
7 terms
form s-3regulatory
"filed a Form S-3 to register the resale of up to 10,045,455 American"
Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.
american depositary sharesfinancial
"resale of up to 10,045,455 American Depositary Shares (ADSs) (representing"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
warrantsfinancial
"could receive up to $88.7 million only if the accompanying warrants are"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
fast track designationregulatory
"has granted Fast Track Designation to its investigational QRX003 lotion"
A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.
orphan drugregulatory
"QRX003 holds Orphan Drug, Rare Pediatric Disease and Fast Track designations"
A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.
rare pediatric diseasemedical
"holds Orphan Drug, Rare Pediatric Disease and Fast Track designations from"
A rare pediatric disease is a serious medical condition that primarily affects children and occurs so infrequently that only a small number of patients exist. Investors care because treatments for such conditions often get special regulatory incentives—think of government fast lanes and rewards for developers—making smaller markets potentially profitable due to pricing power, shorter development timelines, and reduced competition, much like a niche product that receives government-backed advantages.
schedule 13gregulatory
"reported Schedule 13G ownership disclosures for certain ADAR1-related parties"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
ASHBURN, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the first quarter ended March 31, 2026, before the market opens on Thursday, May 7, 2026.
The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from the first quarter of 2026.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009 that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, PC, GS, TSC, microcystic lymphatic malformations, venous malformations, angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
When will Quoin Pharmaceuticals (QNRX) release Q1 2026 financial results?
Quoin will release Q1 2026 financial results before market open on Thursday, May 7, 2026. According to the company, the release covers the quarter ended March 31, 2026 and will be accompanied by a corporate and operational update detailing recent accomplishments.
What will Quoin Pharmaceuticals (QNRX) include in the May 7, 2026 announcement?
The announcement will include an operational update and first quarter financial highlights for Q1 2026. According to the company, it will highlight key achievements from the quarter and recent accomplishments alongside financial results.
How can investors access Quoin Pharmaceuticals (QNRX) May 7, 2026 corporate update?
Investors should check Quoin's investor relations channels for the May 7, 2026 release before market open. According to the company, details and materials related to the operational update and financial highlights will be posted via official IR channels.
Which period do the QNRX financial results announced May 7, 2026 cover?
The results cover the quarter ended March 31, 2026. According to the company, the May 7 announcement will present financial highlights and an operational summary for Q1 2026.
Will Quoin Pharmaceuticals (QNRX) discuss clinical progress in the May 7, 2026 update?
The company said the update will include recent accomplishments, which may cover clinical progress alongside operational items. According to the company, the operational update will highlight key achievements from the quarter.
